FILE:BIIB/BIIB-8K-20070629154716.txt.gz
EVENTS:	Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers	Financial Statements and Exhibits
TEXT:
ITEM: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM: Financial Statements and Exhibits
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
ITEM 5.02.   DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
       On June 29, 2007, Biogen Idec Inc. announced the resignation of Executive Vice President, Finance and Chief Financial Officer Peter Kellogg. A copy of the press release is attached hereto as Exhibit 99.1 and its contents are incorporated herein by reference.
ITEM 9.01   FINANCIAL STATEMENTS AND EXHIBITS.
(d)   Exhibits
       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: June 29, 2007

 
Exhibit 99.1
Tim Hunt, Vice President Public Affairs (617) 914-6524
For More Information Contact: Biogen Idec Media Contact:
Elizabeth Woo, Vice President Investor Relations (617) 679-2812
Investment Community Contact:
BIOGEN IDEC ANNOUNCES MANAGEMENT CHANGE
 Biogen Idec (NASDAQ: BIIB) announced today that Peter Kellogg, Executive Vice President, Finance & Chief Financial Officer (CFO) will leave the organization to become CFO at Merck & Co., Inc.
Cambridge, MA (June 29, 2007)
"I want to thank Peter for his seven years of distinguished service to the organization," stated James C. Mullen, Biogen Idec's President and Chief Executive Officer. "Peter is a world-class financial executive who helped Biogen Idec grow our core therapeutic areas, execute several significant deals, and expand our global footprint. We wish him all the best with his new assignment at Merck."
Mr. Kellogg will leave Biogen Idec on August 10. The Company will announce its plans regarding the CFO position over the next several weeks.
About Biogen Idec
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit .
www.biogenidec.com


